Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor

BACKGROUND: Imatinib mesylate has been used for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST). The current recommended dose of imatinib is 400 mg/day that is increased to 800 mg/day in cases with disease progression. However, imatinib can be associated with diver...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Jun-Eul, Yoon, Ju-Young, Bae, Woo-Kyun, Shim, Hyun-Jeong, Cho, Sang-Hee, Chung, Ik-Joo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936326/
https://www.ncbi.nlm.nih.gov/pubmed/20718969
http://dx.doi.org/10.1186/1471-2407-10-438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936326/
https://www.ncbi.nlm.nih.gov/pubmed/20718969
http://dx.doi.org/10.1186/1471-2407-10-438

Ejemplares similares